Commentary

Video

Dr Werutsky on the Effects of HER2-Low Breast Cancer Subtype on Treatment Outcomes

Gustavo Werutsky, MD, PhD, discusses an exploratory analysis that outlined associations between HER2-low breast cancer subtype and clinical outcomes.

“The intrinsic subtypes of HER2 low are prognostic, and they [result in] different outcomes in 5 years.”

Gustavo Werutsky, MD, PhD, medical oncologist, Breast Cancer Program, Hospital Moinhos de Vento; investigator, Oncology Research Centre, Hospital São Lucas PUCRS University, discusses findings from an exploratory analysis of the phase 3 EORTC10041/BIG 03-04 MINDACT trial (NCT00433589) that characterized HER2-low early breast cancer by molecular subtype and outlined associations between HER2-low subtype and clinical outcomes with chemotherapy and endocrine therapy.

This analysis included 2320 patients with HER2-low tumors, defined as tumors that were HER2 1+ or 2+ nonamplified by immunohistochemistry. Patients were classified into 4 HER2 subtypes: luminal A, luminal B, HER2 enriched, and basal. Genomic risk was assessed using the MammaPrint 70-gene signature.

The MammaPrint test classified 68.4% of tumors as low risk and 31.5% of tumors as high risk (P < .0001). Among HER2 1+ tumors (n = 1505), 74.8% and 25.2% were low and high risk, respectively. Among HER2 2+ tumors (n = 815), these respective rates were 56.9% and 43.1% (P < .0001). Among patients with HER2 1+ disease, 74.2% had luminal A disease, 18.1% had luminal B disease, 74.8% had MammaPrint low-risk disease, and 25.2% had MammaPrint high-risk disease. These respective rates among patients with HER2 2+ disease were 56.2%, 34.6%, 56.9%, and 43.1%.

Investigators also explored the prognostic capabilities of MammaPrint. Patients in this analysis with MammaPrint low-risk disease had a 5-year distant metastasis-free survival (DMFS) rate of 96.5% (95% CI, 95.6%-97.4%) vs 92.5% (95% CI, 90.5%-94.4%) among those with MammaPrint high-risk disease (HR, 1.9; 95% CI, 1.4-2.5; P < .0001). The 5-year DMFS rates among patients with luminal A and luminal B disease, respectively, were 96.5% (95% CI, 95.5%-97.4%) and 92.8% (95% CI, 90.7%-95.1%). These findings showed that clinical outcomes in HER2-low early breast cancer are associated with MammaPrint genomic risk, Werutsky concludes.

Related Videos
Bhavana Pothuri, MD
Kristen Spencer, DO
Laurence Albigès, MD, PhD
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bhagirathbhai Dholaria, MBBS
Sairah Ahmed, M.D
Joshua K. Sabari, MD
Barry W. Goy, MD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
MATT WAGAR, MD